Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Fintech Innovation ETF (ARKF) vs Becton Dickinson and Co (BDX) Price & Performance

ARK Fintech Innovation ETFTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

ARK Fintech Innovation ETF vs Becton Dickinson and Co — how do they compare? ARK Fintech Innovation ETF trades at $43, while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co pays a 2.34% dividend while ARK Fintech Innovation ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.

ARKFBDX
Sector
Sector/ThematicHealth
52-Week High
$58.82$185.39
52-Week Low
$36.14$138.62
Market Cap
$48.93B
Enterprise Value
$65.03B
Dividend Yield
2.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Fintech Innovation ETF

ARKF trades at $42.54, up 1.48% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has underperformed the S&P 500, down 23% since July 2025, and faces elevated volatility. Recent news highlights its fintech and crypto exposure amid market consolidation, with a Hold rating due to fair valuation concerns.

Outlook remains cautious; high P/E of 33x and PEG of 2.0x suggest overvaluation risks, while sector consolidation offers potential recovery if market sentiment improves. Key risks include sustained underperformance and portfolio volatility, requiring careful monitoring of fintech sector trends.

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Fintech Innovation ETF

ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.

Read more on ARKF

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX